Literature DB >> 20837384

The limitations and risks of transarterial Onyx injections in the treatment of grade I and II DAVFs.

Xianli Lv1, Chuhan Jiang, Youxiang Li, Lian Liu, Jie Liu, Zhongxue Wu.   

Abstract

BACKGROUND AND
OBJECTIVE: Embolization of grade III-V intracranial DAVFs using Onyx is feasible with promising results, indicating stability at the time of mid-term follow-up. This article is to evaluate the role of transarterial Onyx embolization in the treatment of grade I and II intracranial dural arteriovenous fistulas (DAVFs), including its limitations and risks.
METHODS: We retrospectively studied consecutive 26 patients (8 women and 18 men) treated for an grade I and II intracranial DAVF since 2006 in whom a transarterial approach was attempted with Onyx-18 embolization. There were 18 transverse-sigmoid sinus, 4 cavernous sinus, 2 superior sagittal sinus, 1 inferior petrosal sinus and 1 intradiploic fistulas. Five fistulas were Type I, 8 were Type IIa, and 13 were Type IIa+b, according to the Cognard classification. The mean clinical follow-up period was 15.6 months.
RESULTS: Anatomic cure was proven in 13 patients (50%) and clinical cure was obtained in 17 cases (65.4%). These 13 cures were achieved after a single procedure. All these 13 patients underwent a follow-up angiography, which has confirmed the complete cure. Partial occlusion was obtained in 13 patients. Complications were as follows: 2 cardiac Onyx migration, 2 reflexive bradyarrythmia, 1 transient visual hallucination, 2 transient fifth nerve palsies and 1 permanent seventh nerve palsy in inferior petrosal sinus DAVF.
CONCLUSIONS: Based on this experience, grade I and II intracranial DAVFs may be treated with transarterial Onyx embolization to reduce the shunted blood flow and to facilitate subsequent transvenous embolization or surgery.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837384     DOI: 10.1016/j.ejrad.2010.08.029

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  [Peripheral facial palsy after embolization of a dural arteriovenous fistula with Onyx®].

Authors:  T J Kupfer; K Aumann; R Laszig; S Meckel
Journal:  HNO       Date:  2011-05       Impact factor: 1.284

2.  Delayed dural arteriovenous fistula after microvascular decompression for hemifacial spasm.

Authors:  Sung Han Kim; Won Seok Chang; Hyun Ho Jung; Jin Woo Chang
Journal:  J Korean Neurosurg Soc       Date:  2014-08-31

Review 3.  Endovascular Management of Intracranial Dural Arteriovenous Fistulas: Transarterial Approach.

Authors:  K D Bhatia; H Lee; H Kortman; J Klostranec; W Guest; T Wälchli; I Radovanovic; T Krings; V M Pereira
Journal:  AJNR Am J Neuroradiol       Date:  2021-10-07       Impact factor: 3.825

4.  Transarterial Treatment of Cranial Dural Arteriovenous Fistulas: The Role of Transarterial and Transvenous Balloon-Assisted Embolization.

Authors:  J O Zamponi; F P Trivelato; M T S Rezende; R K Freitas; L H de Castro-Afonso; G S Nakiri; T G Abud; A C Ulhôa; D G Abud
Journal:  AJNR Am J Neuroradiol       Date:  2020-10-01       Impact factor: 3.825

5.  Transvenous balloon-assisted transarterial Onyx embolization of transverse-sigmoid dural arteriovenous malformation.

Authors:  Pakrit Jittapiromsak; Léon Ikka; Nidhal Benachour; Laurent Spelle; Jacques Moret
Journal:  Neuroradiology       Date:  2012-11-21       Impact factor: 2.804

6.  Angioarchitecture of transverse-sigmoid sinus dural arteriovenous fistulas: evaluation of shunted pouches by multiplanar reformatted images of rotational angiography.

Authors:  H Kiyosue; S Tanoue; M Okahara; Y Hori; J Kashiwagi; Y Sagara; T Kubo; H Mori
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-21       Impact factor: 3.825

7.  Efficacy and limitations of transarterial acrylic glue embolization for intracranial dural arteriovenous fistulas.

Authors:  Naoko Miyamoto; Isao Naito; Tatsuya Shimizu; Yuhei Yoshimoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-01-23       Impact factor: 1.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.